Paradigm Biopharmaceuticals Management

Management criteria checks 3/4

Paradigm Biopharmaceuticals' CEO is Paul Rennie, appointed in Jan 2014, has a tenure of 10.83 years. total yearly compensation is A$1.10M, comprised of 86.5% salary and 13.5% bonuses, including company stock and options. directly owns 2.72% of the company’s shares, worth A$2.67M. The average tenure of the management team and the board of directors is 4.3 years and 4.1 years respectively.

Key information

Paul Rennie

Chief executive officer

AU$1.1m

Total compensation

CEO salary percentage	86.5%
CEO tenure	10.8yrs
CEO ownership	2.7%
Management average tenure	4.3yrs
Board average tenure	4.1yrs

Recent management updates

Recent updates

Paradigm Biopharmaceuticals (ASX:PAR) Is In A Strong Position To Grow Its Business

Aug 22

Here's Why We're Not At All Concerned With Paradigm Biopharmaceuticals' (ASX:PAR) Cash Burn Situation

Apr 17

Companies Like Paradigm Biopharmaceuticals (ASX:PAR) Are In A Position To Invest In Growth

Sep 21

Here's Why We're Not Too Worried About Paradigm Biopharmaceuticals' (ASX:PAR) Cash Burn Situation

Jun 20

Companies Like Paradigm Biopharmaceuticals (ASX:PAR) Are In A Position To Invest In Growth

Dec 02

Companies Like Paradigm Biopharmaceuticals (ASX:PAR) Are In A Position To Invest In Growth

Jun 07

Is Paradigm Biopharmaceuticals Limited (ASX:PAR) Trading At A 46% Discount?

Feb 22

We're Not Worried About Paradigm Biopharmaceuticals' (ASX:PAR) Cash Burn

Jan 24

Did You Participate In Any Of Paradigm Biopharmaceuticals' (ASX:PAR) Incredible 811% Return?

Dec 28

When Will Paradigm Biopharmaceuticals Limited (ASX:PAR) Turn A Profit?

Nov 29

CEO Compensation Analysis

How has Paul Rennie's remuneration changed compared to Paradigm Biopharmaceuticals's earnings?
Date	Total Compensation	Salary	Company Earnings
Jun 30 2024	AU$1m	AU$948k	-AU$59m
Mar 31 2024	n/a	n/a	-AU$64m
Dec 31 2023	n/a	n/a	-AU$69m
Sep 30 2023	n/a	n/a	-AU$60m
Jun 30 2023	AU$2m	AU$602k	-AU$52m
Mar 31 2023	n/a	n/a	-AU$48m
Dec 31 2022	n/a	n/a	-AU$44m
Sep 30 2022	n/a	n/a	-AU$42m
Jun 30 2022	AU$1m	AU$219k	-AU$39m
Mar 31 2022	n/a	n/a	-AU$40m
Dec 31 2021	n/a	n/a	-AU$41m
Sep 30 2021	n/a	n/a	-AU$37m
Jun 30 2021	AU$1m	AU$510k	-AU$34m
Mar 31 2021	n/a	n/a	-AU$31m
Dec 31 2020	n/a	n/a	-AU$28m
Sep 30 2020	n/a	n/a	-AU$20m
Jun 30 2020	AU$632k	AU$462k	-AU$12m
Mar 31 2020	n/a	n/a	-AU$14m
Dec 31 2019	n/a	n/a	-AU$16m
Sep 30 2019	n/a	n/a	-AU$16m
Jun 30 2019	AU$1m	AU$420k	-AU$16m
Mar 31 2019	n/a	n/a	-AU$11m
Dec 31 2018	n/a	n/a	-AU$7m
Sep 30 2018	n/a	n/a	-AU$7m
Jun 30 2018	AU$573k	AU$380k	-AU$6m

Compensation vs Market: Paul's total compensation ($USD712.80K) is above average for companies of similar size in the Australian market ($USD298.50K).

Compensation vs Earnings: Paul's compensation has been consistent with company performance over the past year.

CEO

Paul Rennie (65 yo)

10.8yrs

Tenure

AU$1,096,287

Compensation

Mr. Paul John Rennie, BSc, MBM, Grad Dip Commercial Law, MSTC, served as Independent Non-Executive Chairman at NeuroScientific Biopharmaceuticals Limited since June 21, 2021 until November 23, 2022, was it...

Leadership Team

Name	Position	Tenure	Compensation	Ownership
Paul Rennie	Founder	10.8yrs	AU$1.10m	2.72% A$ 2.7m
Donna Skerrett	Chief Medical Officer and Executive Director	2.3yrs	AU$1.23m	0.31% A$ 306.4k
Abby Macnish Niven	Company Secretary & CFO	2.3yrs	no data	no data
Ravi Krishnan	Chief Scientific Officer	9.2yrs	no data	no data
Simon White	Director of Investor Relations	no data	no data	no data
Michael Imperiale	Global Head of Drug Safety & MPS	4.4yrs	no data	no data
Beverley Huttmann	Commercial Head	4.1yrs	no data	no data
Michelle Coffey	Global Head of Regulatory Affairs	no data	no data	no data
Mukesh Ahuja	Global Clinical Head of OA	no data	no data	no data

4.3yrs

Average Tenure

Experienced Management: PAR's management team is considered experienced (4.3 years average tenure).

Board Members

Name	Position	Tenure	Compensation	Ownership
Paul Rennie	Founder	10.5yrs	AU$1.10m	2.72% A$ 2.7m
Donna Skerrett	Chief Medical Officer and Executive Director	4.3yrs	AU$1.23m	0.31% A$ 306.4k
Amos Meltzer	Independent & Non-Executive Director	3.9yrs	AU$88.80k	no data
Matthew Fry	Independent Non-Executive Director	less than a year	AU$24.24k	0.41% A$ 397.5k

4.1yrs

Average Tenure

65yo

Average Age

Experienced Board: PAR's board of directors are considered experienced (4.1 years average tenure).

Paradigm Biopharmaceuticals Management

Management criteria checks 3/4

Key information

Recent management updates

Donna Skerrett Steps Down from Position as an Executive Director on the Board of Paradigm Biopharmaceuticals Ltd

Non-Executive Director recently bought AU$73k worth of stock

Paradigm Biopharmaceuticals Limited, Annual General Meeting, Nov 19, 2024

Insufficient new directors

Paradigm Biopharmaceuticals Ltd Announces Resignation of John Gaffney as Independent Non Executive Director, Effective Immediately

Paradigm Biopharmaceuticals Limited, Annual General Meeting, Nov 29, 2023

Recent updates

Donna Skerrett Steps Down from Position as an Executive Director on the Board of Paradigm Biopharmaceuticals Ltd

Paradigm Biopharmaceuticals Ltd Plans to Submit the Finalized Protocol for Its Phase 3 Clinical Trial

Non-Executive Director recently bought AU$73k worth of stock

Paradigm Biopharmaceuticals Limited, Annual General Meeting, Nov 19, 2024

New minor risk - Profitability

Insufficient new directors

New minor risk - Share price stability

New minor risk - Shareholder dilution

New minor risk - Market cap size

New minor risk - Share price stability

Paradigm Biopharmaceuticals Ltd Announces Resignation of John Gaffney as Independent Non Executive Director, Effective Immediately

Consensus EPS estimates fall from profit to AU$0.18 loss

Forecast breakeven date pushed back to 2025

Paradigm Biopharmaceuticals Limited, Annual General Meeting, Nov 29, 2023

Full year 2023 earnings: Revenues exceed analysts expectations while EPS lags behind

Paradigm Biopharmaceuticals (ASX:PAR) Is In A Strong Position To Grow Its Business

Founder recently bought AU$76k worth of stock

Here's Why We're Not At All Concerned With Paradigm Biopharmaceuticals' (ASX:PAR) Cash Burn Situation

Paradigm Biopharmaceuticals Ltd Advises the First Safety Review Meeting of the Data Monitoring Committee (DMC) for the Pivotal Para_OA_002 Clinical Trial

Founder recently bought AU$62k worth of stock

Paradigm Biopharmaceuticals Limited Announces Executive Changes

Price target increased to AU$2.20

Paradigm Biopharmaceuticals Limited Announces an Abstract on Paradigm's Phase 2 Clinical Trial Evaluating Injectable Pentosan Polysulfate Sodium

Paradigm Biopharmaceuticals Limited Announces First UK Subject Randomised and Dosed for the Pivotal Phase 3 Trial for the Treatment of Pain Associated with Knee OA

Paradigm Biopharmaceuticals Ltd Announces Successful Primary Endpoint in Phase 2 Trial

Paradigm Biopharmaceuticals Ltd Provides an Update on the Ongoing Multi-Centre Double-Blind Randomised Phase 2 Study Comparing PPS to Placebo in Mucopolysaccharidosis Type VI (MPS-VI) Patients

Paradigm Biopharmaceuticals Limited, Annual General Meeting, Nov 18, 2022

Companies Like Paradigm Biopharmaceuticals (ASX:PAR) Are In A Position To Invest In Growth

Paradigm Biopharmaceuticals Limited Appoints Abby Macnish as Interim Company Secretary

Paradigm Biopharmaceuticals Ltd Announces MPS Clinical Program Update and Paradigm to Present At the International Conference on Lysosomal Diseases

Paradigm Biopharmaceuticals Limited Reports Important Global Progress for the Para_Oa_002 Phase 3 Clinical Trial Evaluating Zilosul® for Osteoarthritis

Paradigm Biopharmaceuticals Limited Announces PARA_OA_008 Study Evaluating Zilosul® Mechanism and Disease Modifying Effects Completes Recruitment

Forecast to breakeven in 2024

Here's Why We're Not Too Worried About Paradigm Biopharmaceuticals' (ASX:PAR) Cash Burn Situation

Paradigm Biopharmaceuticals Limited Announces Chief Executive Officer Changes

Paradigm Biopharmaceuticals Limited Doses First US Subjects Under Phase 3 Trial

Price target decreased to AU$2.64

U.S. Food and Drug Administration Grants Fast Track Designation for Paradigm Biopharmaceuticals Ltd of Phase 3 Program

Founder & Non-Executive Chairman recently bought AU$51k worth of stock

Price target increased to AU$4.49

Consensus forecasts updated

No longer forecast to breakeven

Paradigm Biopharmaceuticals Limited Announces First Subjects Randomised and Dosed in Para_0A_002 Phase 3 Study in Australia

Paradigm Biopharmaceuticals Ltd Reports Postive Topline Results in Heart Failure Model

Companies Like Paradigm Biopharmaceuticals (ASX:PAR) Are In A Position To Invest In Growth

Paradigm Biopharmaceuticals Limited Reports Preliminary Results from Phase 2 Mps I Study

Paradigm Biopharmaceuticals Limited Announces First MPS-VI Patient Dosed Under Phase 2 Trial in Brazil Investigating PPS for the Treatment of MPS-VI

Paradigm Biopharmaceuticals Limited Receives Feedback from US FDA on IND Submission

Paradigm Biopharmaceuticals Limited Announces Australian Ethics Approval for Paradigm's ARA_OA_002 Pivotal Phase 3 Clinical Trial in Participants with Knee OA

Paradigm Biopharmaceuticals Limited Makes Progress with Investigational New Drug Application

Consensus EPS estimates increase to -AU$0.15

Paradigm Biopharmaceuticals Limited Receives Key Regulatory Approvals for MPS VI Study

Companies Like Paradigm Biopharmaceuticals (ASX:PAR) Are In A Position To Invest In Growth

Paradigm Biopharmaceuticals Ltd Receives First Revenue Through Physician Prescription of Zilosul to Patients Via the TGA SAS

Paradigm Biopharmaceuticals Ltd Provides an Update on its IND Application to the Us Food and Drug Administration

Paradigm Biopharmaceuticals Limited Updates Phase 2A, Randomised, Double-Blind, Placebo- Controlled Study

Analysts lower EPS estimates to -AU$0.17

New 90-day low: AU$2.28

Is Paradigm Biopharmaceuticals Limited (ASX:PAR) Trading At A 46% Discount?

Paradigm Biopharmaceuticals Ltd Announces It Has Received Ethics Approval for Its Phase 2 Clinical Trial to Evaluate the Treatment Effects of Pentosan Polysulfate Sodium

Paradigm Biopharmaceuticals Limited Appoints Helen Fisher as Non-Executive Director and Chair of the Audit and Risk Committee

Paradigm Biopharmaceuticals Ltd Reports Ongoing Data Update on Patients Who Received Zilosul Under the Therapeutic Goods Administration (TGA) Special Access Scheme

We're Not Worried About Paradigm Biopharmaceuticals' (ASX:PAR) Cash Burn

New 90-day low: AU$2.38

New 90-day low: AU$2.44

Did You Participate In Any Of Paradigm Biopharmaceuticals' (ASX:PAR) Incredible 811% Return?

Paradigm Biopharmaceuticals Ltd Receives the Written Response from the Type-C meeting with the US Food and Drug Administration (FDA) regarding Zilosul® for the Treatment of Osteoarthritis

When Will Paradigm Biopharmaceuticals Limited (ASX:PAR) Turn A Profit?

Paradigm Biopharmaceuticals Limited Announces Resignation of Chris Fullerton as Non- Executive Director